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Abstract
Cardiovascular diseases are the major causes of mor-
tality in patients with chronic kidney disease (CKD). 
The complex process of accelerated athero- and arte-
riosclerosis in CKD is associated with this phenomenon, 
where endothelial dysfunction (ED) is one of the initial 
steps. Hence, the early diagnosis of ED can potentially 
lead to early interventions which could result in a bet-
ter outcome for these patients. Several methodologies 
have been developed for the diagnosis of ED. Laser 
Doppler flowmetry (LDF) enables us to study the mi-
crocirculation continuously in a non-invasive manner. In 
our review we would like to focus on different tests de-
veloped for LDF, like postocclusive reactive hyperaemia, 
local heating, iontophoresis, microdialysis or analysis of 
flowmotion. We would also like to summarize the avail-
able data in CKD with these methodologies to enlighten 
their perspectives in the clinical use on this patient 
population. 
© 2013 Baishideng. All rights reserved.
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Core tip: Atherosclerotic diseases are the leading 
causes of death in chronic kidney disease (CKD) pa-
tients. Endothelial dysfunction is an important initial 
step of atherosclerotic processes, so with the early di-
agnosis and treatment of endothelial dysfunction many 
cardiovascular events can potentially be prevented. 
Laser Doppler flowmetry (LDF) gives the opportunity 
of the non-invasive study of microcirculation and en-
dothelial function. This review summarizes the results 
of different LDF techniques and their usefulness in the 
diagnosis of endothelial dysfunction in CKD patients.
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ENDOTHELIAL DYSFUNCTION AS AN 
INITIAL STEP OF ATHEROSCLEROSIS 
Endothelial dysfunction (ED) has been implicated as one 
of  the major pathophysiological mechanisms contribut-
ing to the development of  atherosclerosis. ED refers to 
the impairment in the homeostatic properties of  the en-
dothelial layer, like endothelium-dependent regulation of  
vascular tone, hemostasis, permeability, cell adhesion and 
inflammation. Endothelial dysfunction or more correctly 
“endothelial activation” is considered as a key initiating 
step in atherogenesis and also contributes to arterial stiff-
ening. Besides, endothelial dysfunction is predictive of  
cardiovascular events in patients with established cardio-
vascular disease[1].
MINIREVIEWS
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EVIDENCE OF ENDOTHELIAL 
DYSFUNCTION IN CHRONIC KIDNEY 
DISEASE
Patients with chronic kidney disease (CKD) are at high 
risk of  cardiovascular disease, and often suffer from ac-
celerated atherosclerosis[2,3]. CKD can progress to end 
stage renal failure however patients are more likely to die 
of  a cardiovascular disease before reaching the terminal 
renal stage[4,5]. Although classic cardiovascular risk factors 
like hypertension, diabetes and obesity are present and 
frequent in this population, excessive and accelerated car-
diovascular diseases cannot be explained by these alone. 
There is plenty of  evidence indicating that ED has 
high importance in patients with CKD[5-8]. ED begins 
early in the progression of  CKD, independently of  tra-
ditional cardiovascular risk factors, and is also observed 
in children with CKD[9-11]. Amongst the pathophysiologi-
cal reasons chronic inflammation and excessive oxida-
tive stress seem to be the most important[5]. The causes 
of  inflammation are multiple, including decreased renal 
function, chronic volume overload, comorbidities, factors 
associated with the dialysis procedure, and genetic fac-
tors. C-reactive protein (CRP) was initially suggested to 
be merely a biomarker of  inflammation, but recent data 
show that circulating CRP is also a mediator of  athero-
genesis and inflammation[12-14]. An inverse relationship 
between CRP and endothelium-dependent vasoreactivity 
has been described, which suggests that CRP can be a 
link between inflammation and ED[15]. 
Nitrogen monoxide (NO) is one of  the most impor-
tant vasodilating substances released by the endothelium. 
In CKD decreased NO level has often been reported and 
is associated with impaired endothelial function. The de-
creased NO may be connected to the reduced endothe-
lial nitric oxide synthase activity which is a consequence 
of  endogenous or exogenous inhibitors. There is some 
evidence for the accumulation of  an endogenous inhibi-
tor of  nitric oxide synthase in haemodialysed patients[16]. 
Asymmetrical dimethyl arginine inhibits NO synthesis, in-
crease vascular resistance and blood pressure[16-18]. There 
is much evidence which suggest that oxidative stress 
also plays an important role in decreased bioavailability 
of  NO in CKD. Oxidative stress markers are elevated 
in CKD and it has been reported that the antioxidant 
vitamin-C microdialysed into the forearm skin improved 
the endothelial function[19,20]. These findings suggest that 
decreased NO availability as a consequence of  increased 
oxidative stress can be another reason of  early ED in 
CKD. 
METHODS FOR THE ASSESSMENT OF 
THE MICROVASCULAR FUNCTION
The cutaneous circulation is an easily accessible vascular 
bed for the assessment of  in vivo human microcirculatory 
function, and may be representative of  systemic vascular 
function[21,22]. Furthermore alterations in microvascular 
function may occur early in the progression of  cardiovas-
cular disease[22,23]. This phenomenon gives the opportuni-
ty that with the study of  cutaneous microcirculation and 
early diagnosis of  ED quick therapeutical interventions 
could be performed to avoid the development of  severe 
cardiovascular events. 
There are several methods for investigating endothe-
lial dysfunction non-invasively. Evaluation of  flow medi-
ated vasodilatation (FMD) by ultrasound is widely used 
to study ED in coronary artery disease, hyperlipidaemia, 
hypertension and diabetes[4]. However, it has become 
more prominent in recent years, that the process is not 
completely dependent on the release of  NO in response 
to increased shear stress, especially the first phase of  the 
hyperaemia[24]. Another approach is to study forearm 
blood flow using venous strain-gauge plethysmography. 
Although this well reproducible method was the gold 
standard in the assessment of  ED for a long time, today 
its daily use is limited because it requires specially trained 
investigators and brachial artery catheterization for the 
administration of  the vasoactive drugs[25]. Recently for the 
assessment of  microvascular function the most widely 
used noninvasive method has been laser Doppler flowm-
etry (LDF) of  the skin.
LASER DOPPLER FLOWMETRY IN THE 
STUDY OF ENDOTHELIAL DYSFUNCTION 
LDF is based on the reflection of  laser beam light. Light 
undergoes changes in wavelength (Doppler shift) when 
it is reflected by the moving red blood cells in the mi-
crovasculature and a photodiode measures the emerged 
beam. The magnitude and frequency distribution of  
these changes in wavelength are related to the number 
and velocity of  moving red blood cells[14,26,27]. Several dif-
ferent signals can be recorded but the red blood cell flux 
is used the most. LDF enables the evaluation of  cutane-
ous microvascular blood flow over time and its changes. 
The LD output is semi-quantitative and expressed in 
perfusion unit (PU) of  output voltage (1 PU = 10 mV) 
in accordance with general consensus (European Laser 
Doppler Users Groups, London 1992). Many techniques 
can be associated to LDF such as local heating, post-
occlusive reactive hyperaemia, iontophoresis, or microdi-
alysis.
DIFFERENT LDF TECHNIQUES IN THE 
ASSESSMENT OF ENDOTHELIAL 
DYSFUNCTION
Postocclusive reactive hyperaemia 
Postocclusive reactive hyperaemia (PORH) refers to 
the increase in skin blood flow following a brief  arterial 
occlusion. The procedure starts with the occlusion of  
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the brachial artery using a pressure cuff  placed around 
the upper arm and inflated up to 20 mmHg above the 
systolic blood pressure. The commonly used ischaemic 
period varies between 3-10 min (unfortunately there is 
no standardized protocol), and a quick deflation finishes 
the procedure. A linear correlation between the period 
of  ischaemia and the amplitude of  the response has been 
reported[27,28]; however the length of  the ischaemic period 
is coupled with the increasing pain of  the subject. Lots 
of  parameters can be calculated from the response curve. 
The most widely used as the primary endpoint is the 
peak hyperaemia after the cuff  release. Other parameters 
used are the area under the hyperaemic curve, the raw 
value of  the peak minus biological zero, the increase in 
postischaemic flow using area under the curve at baseline 
and postischaemia[27,29,30], (Figure 1). Four major factors 
have been thought to play a role in the hyperaemic re-
sponse: metabolic vasodilators, endothelial vasodilators, 
myogenic response to shear stress and sensory nerves. 
Interestingly NO does not play a crucial role in this test, 
because the response to ischaemia is mostly mediated by 
prostanoids[31]. In summary, PORH represents a complex 
microvascular response to an acute period of  ischaemia, 
in which endothelium has a less pronounced role[27]. 
Some clinical data are available with PORH. Yamamoto 
et al[32] found decreased microvascular response during 
PORH test in patients with type 2 diabetes mellitus and 
similar results have been reported in patients with type 1 
diabetes[33]. There are only a few articles in the literature 
that have used PORH in order to study endothelial func-
tion in patients with CKD, and the results are controver-
sial. Stewart et al[29] studied patients with end-stage renal 
disease (ESRD) with and without diabetes and cardiovas-
cular disease. They found decreased hyperaemic response 
in patients with renal disease and also with cardiovascular 
disease and diabetes, but they could not demonstrate dif-
ference between patients with ESRD only and healthy 
controls. Previously we demonstrated decreased peak 
flow values compared to healthy controls both in patients 
with hypertension only and in hypertensive patients with 
ESRD. Among the hypertensive ESRD patients no fur-
ther decrease of  the peak flow was found compared with 
the hypertensive group[34]. In a follow-up study which is 
the only one available so far with LDF in CKD, Kruger 
et al[35] found that although PORH parameters did not 
correlate with Framingham and Cardiorisk cardiovascular 
risk scores, but the magnitude of  peak flow was associ-
ated with the development of  cardiovascular disease. Ac-
cording to these results the magnitude of  the peak flow 
can be a useful PORH parameter in the future, but more 
data are necessary to confirm its value. 
Local thermal hyperaemia
Local thermal hyperaemia leads to a temperature depen-
dent increase in skin blood flow and achieves maximal 
vasodilatation between 42-44ºC. This maximal thermal 
vasodilatation corresponds to the maximal vasodila-
tor capacity of  the vessels[27,36]. Local heating-provoked 
vasodilatation is mediated by at least two independent 
mechanisms: the initial peak during the first 10 min re-
lies on local sensory nerves, and is mediated by an axon 
reflex, which is thought to be dependent on calcitonin 
gene related peptide and substance P. The plateau phase 
which occurs after 20-30 min of  warming is mediated 
by NO[37,38]. Previously it was found, that thermal hy-
peraemia is impaired in type 1 and 2 diabetes and in sys-
temic sclerosis [29,39-41]. In ESRD both DuPont et al[20] and 
Stewart et al[29] have found decreased thermal peaks and 
plateau compared to controls. In the follow-up study of  
Kruger et al[35] it was demonstrated that thermal hyper-
aemia parameters (first and second peak flow and area 
under the curve) were associated significantly with the 
calculated cardiovascular risk using Framingham and Car-
diorisk risk scores. They found that both cardiovascular 
mortality and the development of  congestive heart failure 
were significantly associated with the first thermal peak 
and the plateau. As this study was performed only on 
70 ESRD patients the authors concluded that although 
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Figure 1  Laser Doppler parameters during postocclusive reactive hyperaemia test. a: Resting flow; b: Biological zero during arterial occlusion; c: Peak flow after 
cuff release; d: Time to peak; AUC: Area under the curve after cuff release.
abnormal LDF parameters were sensitive indicators of  
increased cardiovascular risk, but a longitudinal study for 
further diagnostic and prognostic validation of  the meth-
od would have been required[35]. Unfortunately no such 
kind of  study was published so far. In summary, the mag-
nitude of  the thermal peaks and the plateau are promis-
ing parameters of  the local thermal hyperaemia test, but a 
study with higher number of  patients would be required 
to assess further clinical data about its usefulness. 
Iontophoresis
Iontophoresis is based on the principle that a charged 
drug in solution will migrate across the skin under the in-
fluence of  a low intensity electric current[42]. The quantity 
of  the penetrating drug depends on the magnitude and 
duration of  the current applied and on the diffusional 
and electrical characteristics of  the skin. When combined 
with laser Doppler flowmetry this method enables the 
detection of  alterations in cutaneous blood flow in re-
sponse to the delivery of  the vasoactive drug. Usually two 
types of  vasoactive drugs are used; acetylcholine (Ach) 
and sodium nitroprusside (SNP). Ach and SNP are used 
to generate endothelium-dependent and independent 
vasodilatation, respectively[14,27]. A reduction on vascular 
response to Ach with no concurrent reduction in SNP 
response indicates endothelial dysfunction. Vascular re-
sponse during Ach iontophoresis has been found to be 
impaired in obstructive sleep apnea syndrome, obesity, 
diabetes, hypercholesterolemia and hypertension[41,43-45]. 
Data in patients with CKD are controversial. Thang et 
al[46] found that Ach and SNP iontophoresis provoked 
vasodilatation was altered in patients with advanced CKD 
compared to healthy controls. In contrast, Cupisti et al[47] 
found no alternations in the hyperaemic response after 
Ach and SNP iontophoresis in patients with CKD com-
pared to healthy controls. Previously we demonstrated 
decreased SNP and Ach response in hypertensive ESRD 
patients compared to healthy controls and patients with 
hypertension without CKD[34]. These data suggest that 
in conservatively treated CKD patients ED cannot be 
demonstrated with iontophoresis of  Ach and SNP, but in 
ESRD, where marked microvascular alterations are pres-
ent this methodology can have clinical implications. 
Laser Doppler flowmetry coupled with microdialysis
Microdialysis is a technique which enables us to take ions 
or molecules into the interstitial space of  the skin. It can 
be used to deliver pharmacological agents to a small area 
of  tissue so that no confounding systemic effects occur. 
In addition, the concentration of  substances released in 
response to the pharmacological action can be measured 
in the dialysate effluent fluid[27]. This approach has been 
used to assess the role of  NO in postocclusive and ther-
mal hyperaemia and opens a new era in the assessment 
of  human skin microcirculation[37,48]. The major limitation 
of  this technique is its microinvasive approach. There are 
a very limited number of  studies in the literature which 
used microdialysis in CKD patients in order to evalu-
ate endothelial function. Dupont et al[20] combined local 
heating with dialysation of  Ringer solution, ascorbic acid, 
L-arginine and nitro-L-arginine methyl ester (L-NAME) 
in patients with stage 3-4 CKD and age, sex matched 
controls. They found in the CKD patients impaired cuta-
neous vasodilation response to local heating, which could 
have been reversed with the local infusion of  ascorbic 
acid or L-arginine. These findings confirm the results of  
other workers which suggested that oxidative stress plays 
important role in the vascular dysfunction in stage 3-4 
CKD. According to its microinvasive feature, microdi-
alysis will probably be used in the future only for experi-
mental studies on limited number of  patients. 
Analysis of flowmotion
Periodic oscillations of  cutaneous blood flow, also called 
flowmotion, can be quantified by spectral analysis. These 
periodic oscillations correlate well with endothelial func-
tion and spontaneous smooth muscle wall activity. Spec-
tral analysis of  laser Doppler signal allows five different 
frequency intervals to be detected. These oscillations 
represent the influence of  the heartbeat (1 Hz), respira-
tion (0.3 Hz), myogenic activity (0.1 Hz), neurogenic 
activity (0.04 Hz), and the frequency sub-interval of  0.01 
Hz is mostly endothelium dependent[49-51]. The only study 
which investigated the skin blood flow oscillations dur-
ing laser Doppler flowmetry in CKD found blunted post 
ischemic increase of  the endothelium dependent skin 
blood flowmotion sub-interval, which can be considered 
as an early sign of  microvascular endothelial dysfunction 
in this patient population[52]. So more data are needed 
with this operator-independent LDF method to discover 
its usefulness in CKD patients.
CRITICAL ASPECTS OF LDF
One major limitation of  LDF is, that it is not possible 
to measure absolute perfusion values. Measurements in 
most studies are expressed in arbitrary units called PU 
and are referred to as flux rather than flow. Moreover, 
laser Doppler has often considered poorly reproducible, 
but when the recording site is standardized, and tempera-
ture controlled room and heated probes were used, the 
day to day reproducibility of  PORH, thermal hyperaemia 
and iontophoresis compares well with that of  flow medi-
ated dilatation of  the brachial artery[27,53]. Besides there 
are some difficulties in interpreting observational studies 
of  patients with CKD because many diseases that cause 
CKD (e.g., diabetes mellitus, hypertension) themselves are 
already associated with endothelial dysfunction. In addi-
tion there are no standardized protocols available with 
the different methods of  LDF, which makes it highly dif-
ficult to compare data from different studies. 
CONCLUSION
Epidemiological evidence has already established the 
connection between CKD and cardiovascular disease[35,54]. 
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ED plays a major role in this linkage. Therefore early 
detection of  ED in CKD would be very important. 
Among other possibilities the measurement of  surrogate 
markers like C-reactive protein, homocysteine, circulating 
selectins, plasminogen activator inhibitor-1, and asym-
metric dimethylarginine[55,56], or semi-invasive techniques 
such as strain-gauge plethysmography and FMD can be 
mentioned. An advantage of  LDF over these methods is 
that it gives a good opportunity for the direct, real time 
assessment of  microvascular function in a non invasive 
manner. Furthermore LDF is an easy and relatively cost 
effective technique which offers the opportunity of  fu-
ture clinical implications. 
But unfortunately we are far from this in CKD. 
Among the above described LDF methodologies PORH 
and local thermal hyperaemia have the only evidence in 
CKD in respect of  prediction of  cardiovascular events. 
However, these data originate from only one follow-up 
study which was performed on a low number of  patients. 
In summary, much more studies are required to assess the 
predictive value of  different parameters evaluated with 
different tests in CKD, before LDF would gain clinical 
application. 
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